检索结果-南通市图书馆

Intraocular pressure lowering efficacy and safety of travoprost 0.004 % as a replacement therapy in patients with open angle glaucoma or ocular hypertension

引用

Chinese Medical Journal 2010年第11期123卷 1417-1421页

作者： GE Jian SUN Xing-huai WANG Ning-li ZHAO Jia-liang WU Ling-ling CHEN Xiao-ming WANG Zhi-xin Benny Li Zhongshan Ophtllalmic Center State Key Laboratory ofOphthalmology Sun Yat-sen University Guangzhou Guangdong510060 China Department of Ophtthalmology Eye Ear Nose and Throat HospitalSchool of Medicine Fudan University Shanghai 200031 China Beijing Tongren Eye Center Beijing Tongren Hospital CapitalMedical University Beijing Ophthalmology & Visual SciencesKey Laboratory Beijing 100730 China Department of Ophthalmology Peking Union Medical CollegeHospital Chinese Academy of Medical Sciences Beijing 100730China Peking University Eye Center Peking University Third HospitalBeijing 100191 China Depal~ment of Ophthalmology West China Hospital SichuanUniversity Chengdu Sichuan 610041 China Alcon Research Ltd. 6201 South Freeway Fort Worth Texas76134 USA

Background travoprost has been widely used for the treatment of patients with open-angle glaucoma （OAG） or ocular hypertension （OH）. The aim of this study was to evaluate the intraocular pressure （lOP） lowering efficacy of travoprost 0.004% monotherapy in patients previously treated with other topical hypotensive medications, and in previously untreated patients. Methods This open-label, 12-week study in 1651 adult patients with ocular hypertension or open-angle glaucoma who were untreated or required a change in therapy （due to either inadequate efficacy or safety issues） as judged by the investigator was conducted at 6 sites in China. Previously treated patients were instructed to discontinue their prior medications at the first visit. All the patients were dosed with travoprost 0.004% once-daily at 8 p.m. in both eyes for 12 weeks. Efficacy and safety evaluations were conducted at week 4 and 12. lOP measurements were performed at the same time of day at the follow-up visits. Results For patients transitioned to travoprost, mean lOP reductions from baseline in untreated and treated patients with different prior medications at week 12 were： latanoprost, （4.3±4.6） mmHg; β-blocker, （6.3±4.0） mmHg; α-agonist, （7.5±4.3） mmHg; topical carbonic anhydrase inhibitors, （8.0±4.9） mmHg. All mean lOP changes from baseline were statistically significant （P 〈0.001）. No treatment-related serious adverse events were reported in this study. Conclusions In patients treated with other hypotensive medications or untreated, the lOP reduction with travoprost was significant. The results of this study demonstrated the potential benefit of using travoprost as a replacement therapy in order to ensure adequate lOP control. travoprost administered once daily was safe and well tolerated in patients with glaucoma or ocular hypertension.

关键词： travoprost prostaglandin analogue intraocular pressure glaucoma

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Acute Uveitis in Neovascular Glaucoma Patient after a Single Dose of travoprost

引用

Case Reports in Clinical Medicine 2024年第8期13卷 275-282页

作者： Lijun Wang Jing Zhu Qian Feng Junfeng Yang Department of Ophthalmology The Third Peoples Hospital of Chengdu College of Medicine Southwest Jiaotong University Chengdu China

A 38-year-old man with no history of uveitis developed neovascular glaucoma (NVG) due to proliferative diabetic retinopathy (PDR). He had a history of ocular surgery with placement of glaucoma drainage implants (GDI), ultrasonic phacoemulsification, and intraocular lens implantation in both eyes. The patient had undergone a recent pars plana vitrectomy with complete panretinal photocoagulation (PRP) to clear vitreous hemorrhage in his right eye. To prevent progressive optic nerve damage, travoprost was tentatively administered because of inadequate intraocular pressure (IOP) control following surgery, laser treatment, and topical administration of many other IOP-lowering drugs. The patient experienced severe vision loss associated with acute anterior and intermediate uveitis. We consider it a rare complication due to the NVG patient’s vulnerability following ocular surgery. Given that acute uveitis developed rapidly and required time to resolve, systemic corticosteroid treatment could be considered to accelerate the resolution of inflammation.

关键词： travoprost Uveitis Glaucoma Prostaglandin Analogues Intraocular Pressure

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Improvement of MDA and SOD Expression and Optic Neuroprotection in Glaucoma Mice by travoprost and β-Blocker

引用

Chinese Journal of Biomedical Engineering(English Edition) 2023年第2期32卷 73-78页

作者： LIU Hai-hua LIN Yi-long ZHONG Jun-mu LIU Jian-qiang Longyan First Affiliated Hospital of Fujian Medical University Fujian Longyan 364000China

Objective:The goal of this study was to see if travoprost and β-blockers improved MDA and SOD expression as well as neuroprotection in glaucoma ***:One hundred healthy SPF SD rats were randomly allocated into five groups:travoprost and β-blocker group,travoprost group,β-blocker group,model group and blank group,with 20 rats in each *** created a glaucoma mouse model in which the blank group and the model group received the same volume of saline,the β-blocker group received β-blocker,the travoprost group received travoprost,and the travo Prost and β-blocker groups received travo Prost and βreceptor *** cell apoptosis level,intraocular pressure level,MDA and SOD levels were measured after drug ***:The results showed that the levels of intraocular pressure,the apoptosis rate of optic nerve,SOD and MDA of retina in travoprost and β-blocker group,travoprost group,β-blocker group and model group were greater than those in blank group(Ptravoprost and β-blocker group continued to fall,while the retinal SOD level was considerably elevated(Ptravoprost and β-blocker resulted in a constant drop in intraocular pressure,optic nerve apoptosis rate and MDA level in the retina,whereas the SOD level was dramatically elevated(Ptravoprost in combination with a β-blocker can greatly increase MDA expression,SOD and neuroprotection.

关键词： travoprost β-blocker glaucoma optic nerve protection

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Comparative Evaluation of the Efficacy of the Bimatoprost 0.03%, Brimonidine 0.2%, Brinzolamide 1%, Dorzolamide 2%, and travoprost 0.004%/Timolol 0.5%-Fixed Combinations in Patients Affected by Open-Angle Glaucoma

引用

Open Journal of Ophthalmology 2012年第4期2卷 122-126页

作者： Italo Giuffre Department of Ophthalmology Medical School Catholic University of Rome Rome Italy

Purpose: This is a retrospective, comparative, head-to-head, not commissioned study about the efficacy of bimato-prost 0.03%, brimonidine 0.2%, brinzolamide 1%, dorzolamide 2%, and travoprost 0.004%/timolol 0.5%-fixed combinations in patients affected by na?ve open-angle glaucoma and IOP > 25 mmHg. Patients and Methods: Files from 70 patients (35 M, 35 F, mean age 69.52 y, S.D. 11.56, range: 37-87y) in our Glaucoma Service were retrospectively analyzed as long as 12 months. Every subgroup, including 14 age- and sex-matched patients, was allocated to 1 of the 5 groups of the fixed combinations monotherapy. Data recorded after 3 months follow-up were statistically analyzed by descriptive and ANOVA statistics as percentage of IOP reduction from baseline. Results: All the fixed combinations were effective in lowering IOP. The mean percentage reduction was: brimonidine/timolol 43.57%, dorzolamide/timolol 37.67%, bimatoprost/timolol 35.60%, travoprost/timolol 33.25% and brinzolamide/timolol 23.0%. The brimonidine/timolol fixed combination showed to be statistically significant more effective only than brinzolamide/timolol fixed combination (p = 0.001). Setting the α error to 5%, the power of the study is 26%, phi: 0.842. Discussion: In all this cohort of patients the target IOP was successfully achieved. All the fixed combinations used in this study had a very good profile of efficacy. Brimonidine, dorzolamide, bimatoprost and travoprost/timolol fixed combinations statistically significantly reduced the percentage of IOP from baseline (p = 0.001) more than brinzolamide/timolol fixed combination.

关键词： Bimatoprost 0.03% Brimonidine 0.2% Brinzolamide 1% Dorzolamide 2% travoprost 0.004%/Timolol 0.5% Fixed Combinations Efficacy IOP

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

*** nanoparticles as a new drug vector for glaucoma therapy

引用

Annals of Eye Science 2018年第1期 488-488页

作者： Florence Masse Mathieu Ouellette Elodie Boisselier Department of Medicine UniversitéLavalQuebecQCCanada Département d'ophtalmologie Facultéde MédecineCUO-RechercheCentre de recherche du CHU de QuébecHôpital du St-SacrementQuebecQCCanada

Background:Glaucoma is an optical neuropathy affecting over 67 million people in the *** of current active molecules,as travoprost(hydrophobic)is limited when administered by ophthalmic ***,more than 99.9%is discarded due to multiple factors including lacrimal *** retention time of drugs at the cornea leads to their poor *** aim of the project is to develop a drug delivery system allowing the drug penetration through biological *** hypothesis is that a drug delivery system based on gold nanoparticles should enhance the efficiency of the *** main objective is to study the encapsulation ability of gold nanoparticles towards *** specific objectives are(I)the synthesis and characterizations of gold nanoparticles;(II)the establishment of the encapsulation protocol;(III)the method development of the separation of free and encapsulated drugs and;(IV)the quantification of the encapsulated ***:Gold nanoparticles were synthesized by a new method developed in our *** encapsulation protocol was settled using aqueous conditions at 37℃.The separation of free and encapsulated drugs was performed with magnetic *** quantification of the encapsulated drugs was then performed by high performance liquid chromatography and confirmed by UV-visible ***:Gold nanoparticles of 28±1 nm were synthesized and purified according to our new experimental *** encapsulation protocol lasts 5 days in the optimised *** separation method involving magnetic beads was optimized to get rid of non-specific *** travoprost was incubated with the nanoparticles until the reach of equilibrium in ***:We showed that active molecules used for glaucoma therapy,as travoprost,can be encapsulated in gold *** analysis will allow identifying the encapsulation properties of various gold nanoparticles,differing by their size,shape and chemical s

关键词： Gold nanoparticles drug vector glaucoma travoprost

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：